New approaches to treating chronic obstructive pulmonary disease with Colla corii asini

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and disability worldwide. Its complex etiology involves factors such as smoking, air pollution, genetic susceptibility, and social environment. With the accelerating global aging population and urbanization, the incidence and burden of COPD continue to rise. Current treatment strategies for COPD are relatively conservative, primarily focusing on bronchodilators, inhaled corticosteroids, and long-term oxygen therapy. Although these approaches can alleviate symptoms and slow disease progression to some extent, they fail to effectively target the underlying mechanisms of the disease, leaving an unmet clinical need for more-effective therapies. This highlights the urgency of developing innovative drugs that are both safe and efficacious to address the challenges in COPD treatment. As a traditional Chinese medicine with a long history, Colla corii asini has garnered significant attention for its diverse pharmacological effects and favorable safety profile. Research has shown that Colla corii asini possesses multiple biological activities, including hematopoiesis, nourishing the lungs, enhancing immunity, anti-infection, antiaging, antitumor, and antifatigue effects. Moreover, it has demonstrated potential in regulating oxidative stress, immune imbalance, and inflammatory responses. Recent evidence suggests that Colla corii asini may play a protective role in lung function through multitarget and multipathway mechanisms. Based on previous research findings, this paper explores the potential therapeutic value of Colla corii asini in COPD treatment by addressing the current clinical management challenges and identifying potential therapeutic targets. It also integrates the pharmacological effects of Colla corii asini into a broader treatment context, providing new perspectives for comprehensive COPD management and laying the theoretical foundation for its modernization and innovative application.

Keywords

chronic obstructive pulmonary disease / Colla corii asini / pharmacology / therapeutic targets

References

[1] Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2025 Report. Accessed November 18, 2024. http://www.goldcopd.org

[2] World Health Organization (WHO). Chronic obstructive pulmonary disease. Accessed March 15, 2022. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

[3] Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet. 2007; 370(9589): 741-750.

[4] Hansel NN, McCormack MC, Kim V. The effects of air pollution and temperature on COPD. COPD. 2016; 13(3): 372-379.

[5] Soriano JB, Polverino F, Cosio BG. What is early COPD and why is it important? Eur Respir J. 2018; 52(6):1801448.

[6] Tashkin DP. Smoking cessation in chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2015; 36(4): 491-507.

[7] Montes de Oca M. Smoking cessation/vaccinations. Clin Chest Med. 2020; 41(3): 495-512.

[8] Britto CJ, Brady V, Lee S, Dela Cruz CS. Respiratory viral infections in chronic lung diseases. Clin Chest Med. 2017; 38(1): 87-96.

[9] Qi C, Sun SW, Xiong XZ. From COPD to lung cancer: mechanisms linking, diagnosis, treatment, and prognosis. Int J Chron Obstruct Pulmon Dis. 2022; 17: 2603-2621.

[10] Güder G, Störk S. COPD and heart failure: differential diagnosis and comorbidity. Herz. 2019; 44(6): 502-508.

[11] Zuberi FF, Zuberi BF, Ali FS, Bader N. Muscle weakness assessment in non-hypoxemic COPD out-patients at tertiary care hospitals. Pak J Med Sci. 2021; 37(2): 536-542.

[12] Kham-Ai P, Heaton K, Li P. Association between COPD symptoms and psychological distress among farmers. Workplace Health Saf. 2023; 71(2): 89-95.

[13] Kaur M, Chandel J, Malik J, Naura AS. Particulate matter in COPD pathogenesis: an overview. Inflamm Res. 2022; 71(7–8): 797-815.

[14] Allam VSRR, Faiz A, Lam M, et al. RAGE and TLR4 differentially regulate airway hyperresponsiveness: implications for COPD. Allergy. 2021; 76(4): 1123-1135.

[15] Córdoba-Lanús E, Baz-Dávila R, Espinoza-Jiménez A, et al. IL-8 gene variants are associated with lung function decline and multidimensional BODE index in COPD patients but not with disease susceptibility: a validation study. COPD. 2015; 12(1): 55-61.

[16] Monzon ME, Forteza RM, Casalino-Matsuda SM. MCP-1/CCR2B-dependent loop upregulates MUC5AC and MUC5B in human airway epithelium. Am J Physiol Lung Cell Mol Physiol. 2011; 300(2): L204-L215.

[17] Langen RC, Korn SH, Wouters EF. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med. 2003; 35(3): 226-235.

[18] Hikichi M, Mizumura K, Maruoka S, Gon Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. J Thorac Dis. 2019; 11(Suppl 17): S2129-S2140.

[19] Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J. 2012; 40(6): 1545-1554.

[20] Lea S, Higham A, Beech A, Singh D. How inhaled corticosteroids target inflammation in COPD. Eur Respir Rev. 2023; 32(170):230084.

[21] Beghè B, Rabe KF, Fabbri LM. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med. 2013; 188(3): 271-278.

[22] Patel M, Thomson NC. (R)-salbutamol in the treatment of asthma and chronic obstructive airways disease. Expert Opin Pharmacother. 2011; 12(7): 1133-1141.

[23] Gross NJ, Donohue JF. Nebulized formoterol: a review of clinical efficacy and safety in COPD. Int J Chron Obstruct Pulmon Dis. 2010; 5: 223-232.

[24] Lin S, Li X, Xie B, Yue W, Yao X, Lin M. Ipratropium bromide and noninvasive ventilation treatment for COPD. Am J Transl Res. 2022; 14(5): 3319-3326.

[25] Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017; 377(10): 923-935.

[26] Suissa S, Dell'Aniello S, Ernst P. Fluticasone-based versus budesonide-based triple therapies in COPD: real-world comparative effectiveness and safety. COPD. 2022; 19(1): 109-117.

[27] Williams D. The role of the pharmacist in optimizing outcomes with Roflumilast, a PDE4 inhibitor for the treatment of COPD. J Pharm Pract. 2022; 35(3): 445-454.

[28] Cao X, Wang Y, Chen Y, et al. Advances in traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease. J Ethnopharmacol. 2023; 307:116229.

[29] Zhang Y, Zhao L, Yue Q, et al. Using Traditional Chinese Medicine to Alleviate Chronic Obstructive Pulmonary Disease. Stud Health Technol Inform. 2023; 308: 696-704.

[30] Sun Y, Chen X, Zhang L, et al. Efficiency and safety of Baofei granules in chronic obstructive pulmonary disease (lung and spleen Qi deficiency syndrome): a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial. Drug Des Devel Ther. 2022; 16: 4251-4267.

[31] Hanyu F, Zheng H, Deming LI, et al. Formulation of international standards of Chinese medicine technology: clinical practice guide of Chinese medicine for cough. J Tradit Chin Med. 2024; 44(2): 396-402.

[32] Zhao SC, Wei RL, Xie YM, Wang LX, Wang Q, Yi DH. Analysis of Qingkailing injection in treatment of combined medication features of 2 147 cases of upper respiratory tract infection. Zhongguo Zhong Yao Za Zhi. 2019; 44(23): 5207-5216.

[33] Wang K, Li L, Wang Y, et al. Effect of Baihe Gujin decoction combined with Shengmai powder on the expression of IL-1β and IL-1Ra in peripheral blood CD14⁺ monocytes from patients with pulmonary tuberculosis. Cell Mol Biol (Noisy-le-Grand). 2022; 68(2): 60-63.

[34] Xiao Y, Zhang K, Zhu SY, et al. Shenling Baizhu powder () ameliorates pi (spleen)-deficiency-induced functional diarrhea in rats. Chin J Integr Med. 2021; 27(3): 206-211.

[35] Qian CL, Fan R. Effect of Pingchuan Guben decoction on patients with chronic obstructive pulmonary disease: results from a randomized comparative effectiveness research trial. Exp Ther Med. 2017; 14(4): 3915-3925.

[36] Lin YC, Chang CW, Wu CR. Antitussive, anti-pyretic and toxicological evaluation of Ma-Xing-Gan-Shi-Tang in rodents. BMC Complement Altern Med. 2016; 16(1): 456.

[37] Zhao FD, Dong JC, Cui Y, Xie JY, Wu SM. The effect of Ejiao on airway inflammation and Th1/Th2 cytokines in serum of asthmatic rats. Chin J Exp Tradit Med Formulae. 2006; 2006(6): 59-61.

[38] Zhang G, Guo F, Zeng M, et al. The immune-enhancing effect and in vitro antioxidant ability of different fractions separated from Colla corii asini. J Food Biochem. 2022; 46(11):e14174.

[39] Zhang JJ, Zhang Y, Meng J, et al. Herbalogical study of Colla Corii Asini(Ejiao). Zhongguo Zhong Yao Za Zhi. 2020; 45(10): 2464-2472.

[40] Nazhakaiti A, Hu G, Zhang TT, et al. Effects of Colla corii asini on lung function and pathological injury in rats with chronic obstructive pulmonary disease. Bas Clin Med. 2021; 41(7): 970-974.

[41] Liu T, Zhang P, Ling Y, et al. Protective effect of Colla corii asini against lung injuries induced by intratracheal instillation of artificial fine particles in rats. Int J Mol Sci. 2018; 20(1):55.

[42] Xiao L, Mochizuki M, Fan Y, Nakahara T, Liao F. Enzyme-digested Colla corii asini (E'jiao) suppresses lipopolysaccharide-induced inflammatory changes in THP-1 macrophages and OP9 adipocytes. Hum Cell. 2022; 35(3): 885-895.

[43] Yue Q, Zhang W, Lin S, et al. Ejiao ameliorates lipopolysaccharide-induced pulmonary inflammation via inhibition of NFκB regulating NLRP3 inflammasome and mitochondrial ROS. Biomed Pharmacother. 2022; 152:113275.

[44] Park KI, Lee MR, Oh TW, Kim KY, Ma JY. Antibacterial activity and effects of Colla corii asini on Salmonella typhimurium invasion in vitro and in vivo. BMC Complement Altern Med. 2017; 17(1):520.

[45] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet (London, England). 2021; 397(10284): 1577-1590.

[46] Xiao L, Liao F, Ide R, et al. Enzyme-digested Colla corii asini (E'jiao) prevents hydrogen peroxide-induced cell death and accelerates amyloid beta clearance in neuronal-like PC12 cells. Neural Regen Res. 2020; 15(12): 2270-2272.

[47] Xiao L, Liao F, Fan Y, Miwa N. Correction to: enzyme-digested Colla corii asini (E'jiao) accelerates wound healing and prevents ultraviolet A-induced collagen synthesis decline and wrinkle formation in three-dimensional skin equivalents. Hum Cell. 2021; 34(1): 291.

[48] Batsaikhan T, Choi JS, Ha SM, Ahn Y, Seo YJ. D-galactose and hypoxia induce the early onset of age-related hearing loss deterioration in a mouse model. Tissue Eng Regen Med. 2023; 20(5): 779-787.

[49] Wang D, Liu M, Cao J, et al. Effect of Colla corii asini (E'jiao) on D-galactose induced aging mice. Biol Pharm Bull. 2012; 35(12): 2128-2132.

[50] Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011; 33(4): 369-383.

[51] Lee YY, Irfan M, Quah Y, et al. The increasing hematopoietic effect of the combined treatment of Korean Red Ginseng and Colla corii asini on cyclophosphamide-induced immunosuppression in mice. J Ginseng Res. 2021; 45(5): 591-598.

[52] Li Y, He H, Yang L, Li X, Li D, Luo S. Therapeutic effect of Colla corii asini on improving anemia and hemoglobin compositions in pregnant women with thalassemia. Int J Hematol. 2016; 104(5): 559-565.

[53] Zeng L, Li X, Bai G, Liu Y, Lu Q. Rectal administration of Panax notoginseng and Colla corii asini suppositories in ulcerative colitis: clinical effect and influence on immune function. Am J Transl Res. 2022; 14(1): 603-611.

[54] Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019; 74(7): 1249-1256.

[55] Leelarungrayub J, Puntumetakul R, Sriboonreung T, Pothasak Y, Klaphajone J. Preliminary study: comparative effects of lung volume therapy between slow and fast deep-breathing techniques on pulmonary function, respiratory muscle strength, oxidative stress, cytokines, 6-minute walking distance, and quality of life in persons with COPD. Int J Chron Obstruct Pulmon Dis. 2018; 13: 3909-3921.

[56] Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016; 11: 1413-1424.

[57] Raby KL, Michaeloudes C, Tonkin J, Chung KF, Bhavsar PK. Mechanisms of airway epithelial injury and abnormal repair in asthma and COPD. Front Immunol. 2023; 14:1201658.

[58] Kim RY, Sunkara KP, Bracke KR, et al. A microRNA-21-mediated SATB1/S100A9/NF-κB axis promotes chronic obstructive pulmonary disease pathogenesis. Sci Transl Med. 2021; 13(621):eaav7223.

[59] Janaszak-Jasiecka A, Płoska A, Wierońska JM, Dobrucki LW, Kalinowski L. Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets. Cell Mol Biol Lett. 2023; 28(1): 21.

[60] Kume H, Yamada R, Sato Y, Togawa R. Airway smooth muscle regulated by oxidative stress in COPD. Antioxidants (Basel). 2023; 12(1):142.

[61] Araya J, Tsubouchi K, Sato N, et al. PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis. Autophagy. 2019; 15(3): 510-526.

[62] Zhu H, Jia Z, Misra BR, et al. Nuclear factor E2-related factor 2-dependent myocardiac cytoprotection against oxidative and electrophilic stress. Cardiovasc Toxicol. 2008; 8(2): 71-85.

[63] García-Valero J, Olloquequi J, Rodríguez E, Martín-Satué M, Texidó L, Ferrer J. Decreased expression of EC-SOD and Fibulin-5 in alveolar walls of lungs from COPD patients. Arch Bronconeumol. 2022; 58(6): 482-489.

[64] Chin KY, Ng BN, Rostam MKI, et al. Effects of E'Jiao on skeletal mineralisation, osteocyte and WNT signalling inhibitors in ovariectomised rats. Life (Basel). 2023; 13(2):570.

[65] Wang T, Sun HG, Hua YL, Li PL, Wei YM. Urine metabonomic study for blood-replenishing mechanism of Angelica sinensis in a blood-deficient mouse model. Chin J Nat Med. 2016; 14(3): 210-219.

[66] Yumei F, Wenwen R, Ning S, et al. Effects of dietary intake of Colla corii asini on skin parameters and appearance: results of a 12-week randomized, controlled, open-labeled trial. Pharmacol Res Mod Chin Med. 2022; 2:100065.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.